The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800c > T polymorphism on rosuvastatin pharmacokinetics in chinese healthy males

Pharmazie

Volumn 69, Issue 10, 2014, Pages 775-779

  Lou, Xiao Ya ^a   Zhang, Wei ^a   Wang, Guo ^a   Hu, Dong Li ^a   Guo, Dong ^a   Tan, Zhi Rong ^a   Zhou, Hong Hao ^a   Chen, Yao ^a   Bao, Hei Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ROSUVASTATIN; SODIUM BILE ACID COTRANSPORTER; COTRANSPORTER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PYRIMIDINE DERIVATIVE; SODIUM-BILE ACID COTRANSPORTER; SULFONAMIDE;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORAL CLEARANCE; PYROSEQUENCING; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; EPIDEMIOLOGY; GENETICS;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FLUOROBENZENES; GENE FREQUENCY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; POLYMORPHISM, GENETIC; PYRIMIDINES; SULFONAMIDES; SYMPORTERS;

EID: 84920845899     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2014.4576     Document Type: Article

References (24)

1. Carswell CI, Plosker GL, Jarvis B (2002) Rosuvastatin. Drugs 62: 2075-2085.
2. Chasman DI, Giulianini F, Macfadyen J, Barratt BJ, Nyberg F, Ridker PM (2012) Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 5: 257-264.
3. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K (2008) Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83: 251-257.
4. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS (2011) Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41: 24-34.
5. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA (1998) Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol Gastrointest Liver Physiol 274: G157-G169.
6. Ghatak A, Faheem O, Thompson PD (2010) The genetics of statin-induced myopathy. Atherosclerosis 210:337-343.
7. Greupink R, Dillen L, Monshouwer M, Huisman MT, Russel FG (2011) Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP). Eur J Pharm Sci 44: 487-496.
8. Hagenbuch B, Meier PJ (1996) Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin Liver Dis 16:129-136.
9. Ho RH, Leake BF, Roberts RL, Lee W, Kim RB (2004) Ethnicitydependent polymorphism inNa+ -taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 279: 7213-7222.
10. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806.
11. Huang L,WangY, Grimm S (2006)ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34: 738-742.
12. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86: 197-203.
13. Kim KA, Joo HJ, Park JY (2010) ABCG2 polymorphisms, 34G >A and 421C >A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Thera 35: 705-712.
14. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78: 330-341.
15. Lee HK, Hu M, Lui Sandra SH, Ho CS, Wong CK, Tomlinson B (2013) Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 14: 1283-1294.
16. Link E, Parish S, Armitage J, BowmanL, Health S, Matsude F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genome wide study. N Engl J Med 359: 789-799.
17. PanW, Song IS, Shin HJ, Kim MH, Choi YL, Lim SJ, KimWY, Lee SS, Shin JG (2011) Genetic polymorphisms in Na + /-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica 41: 501-510.
18. Pasanen MK, Neuvonen M, Neuvonen PJ, NiemiM(2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873-879.
19. Pasanen MK, Fredrikson H, Neuvonen PJ, NiemiM(2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82: 726-733.
20. Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G, Lötsch J (2006) Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing. Pharmacogenomics 7: 167-176.
21. Romaine SP, Bailey KM, Hall AS, Balmforth AJ (2009) The influence of SLCO1B1(OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10: 1-11.
22. Tzeng TB, Schneck DW, Birmingham BK (2008) Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin 24: 2575-2585.
23. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13: 19-28.
24. Zhang W, Yu BN, Yu, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Jiang F, Huang YF, Zhou HH (2006) Role of BCRP 421C >A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373: 99-103.